Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. Co.'s suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. We show 22 historical shares outstanding datapoints in our BEAM shares outstanding history coverage, used to compute BEAM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BEAM market cap history over the course of time is important for investors
interested in comparing BEAM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BEAM versus a peer is one thing; comparing
BEAM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BEAM can fluctuate over the course of history.
With this page we aim to empower investors researching BEAM by allowing them to research the BEAM market cap history. |
Free BEAM Email Alerts:
Video: The Importance of Market Cap
